Drug
Cs8635 20 5 And Placebo
Cs8635 20 5 And Placebo: highest development phase Phase 3, developed by Daiichi Sankyo. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Daiichi Sankyo
Trials
| Drug | Phase | Indication |
|---|---|---|
| CS8635 20/5/12.5mg and placebo NCT01838850 | Phase 3 | Essential Hypertension |
Latest
No recent events.
Follow Cs8635 20 5 And Placebo on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.